4571 Stock Overview
Researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NANO MRNA Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥167.00 |
| 52 Week High | JP¥259.00 |
| 52 Week Low | JP¥135.00 |
| Beta | 0.31 |
| 11 Month Change | 1.83% |
| 3 Month Change | -17.33% |
| 1 Year Change | -35.52% |
| 33 Year Change | -43.20% |
| 5 Year Change | -49.09% |
| Change since IPO | -44.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4571 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 3.1% | -6.1% | -0.7% |
| 1Y | -35.5% | 16.5% | 10.8% |
Return vs Industry: 4571 underperformed the JP Biotechs industry which returned 16.5% over the past year.
Return vs Market: 4571 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4571 volatility | |
|---|---|
| 4571 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4571's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4571's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 18 | Shiro Akinaga | www.nanomrna.co.jp |
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer.
NANO MRNA Co.,Ltd. Fundamentals Summary
| 4571 fundamental statistics | |
|---|---|
| Market cap | JP¥11.86b |
| Earnings (TTM) | -JP¥651.00m |
| Revenue (TTM) | JP¥77.00m |
153.1x
P/S Ratio-18.1x
P/E RatioIs 4571 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4571 income statement (TTM) | |
|---|---|
| Revenue | JP¥77.00m |
| Cost of Revenue | JP¥17.00m |
| Gross Profit | JP¥60.00m |
| Other Expenses | JP¥711.00m |
| Earnings | -JP¥651.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.22 |
| Gross Margin | 77.92% |
| Net Profit Margin | -845.45% |
| Debt/Equity Ratio | 34.0% |
How did 4571 perform over the long term?
See historical performance and comparison